A selective beta-1 receptor blocker called betaxolol is used to treat hypertension in patients (Beta-blockers are used as alternative agents for the treatment of hypertension). The following conditions are also treated with it off-label:
- Acute Myocardial infarction
- For rate control in Atrial fibrillation
- Chronic stable angina
- With the purpose of avoiding postoperative atrial fibrillation brought on by heart surgery.
Betaxolol Dose in Adults
Betaxolol dosage as off label use in the treatment of Atrial fibrillation for rate control:
- 20 mg once a day.
- It may be used in combination with digoxin.
Betaxolol dose as Off label use in the treatment of chronic stable angina:
- 20 mg once a day.
Betaxolol dose as an alternative agent in Hypertension:
- 5 to 10 mg once a day.
- The dose is titrated every one to two weeks if required based on the patients' response.
- The maximum dose is 20 mg once a day.
Off label use for preventing postoperative atrial fibrillation associated with cardiac surgery:
- 20 mg once a day.
Dose in children:
It is not recommended for use in children.
Betaxolol Pregnancy Risk Factor C
- Betaxolol crosses over the placental barriers and can be detected in neonatal blood or urine.
- Betaxolol can cause lasting effects in the neonate for up to seven days after delivery.
- Neonatals may experience hypoglycemia and bradycardia. Monitor neonates for three to five days
- Uncontrolled hypertension can also be associated with maternal preeclampsia and neonatal adverse effects.
- Beta-blockers can be used when indicated to treat hypertension during pregnancy. However, it is best to use other preferred agents as first-line.
Use during breastfeeding:
- Breastfeeding mothers should use betaxolol with caution, as it is excreted through breastmilk and can have beta-blocking effect on the baby.
Dose in patients with renal impairment:
-
Severe impairment:
- 5 mg once a day initially.
- Every two weeks, the dosage can be raised up to a maximum of 20 mg once a day.
-
Hemodialysis:
- Daily dose of 5 mg.
- Every two weeks, the dosage may be increased up to a daily maximum of 20 mg.
Dose in patients with liver disease:
Adjustment in the dose is not required.
Side Effects of Betaxolol:
-
Cardiovascular:
- Bradycardia
- Chest Pain
- Cold Extremities
- Palpitations
- Edema
-
Central Nervous System:
- Fatigue
- Insomnia
- Lethargy
- Paresthesia
-
Gastrointestinal:
- Nausea
- Dyspepsia
- Diarrhea
-
Hematologic & Oncologic:
- Positive ANA Titer
-
Neuromuscular & Skeletal:
- Arthralgia
-
Respiratory:
- Dyspnea
- Pharyngitis
Contraindication to Betaxolol include:
- Allergy reactions to betaxolol and any component of the formulation
- Sinus bradycardia
- Heart block of second or third degree
- Cardiogenic shock
- Cardiac failure
Warnings and precautions
- Anaphylactic reactions
- Patients who have had anaphylaxis in the past should be cautious.
- Patients using beta-blockers may be less sensitive to the effects of epinephrine if anaphylaxis develops.
-
Bronchospastic Disease:
- In severe bronchospasm, beta-blockers should be avoided.
- Betaxolol, a selective Beta-1-blocker, can be used in low doses (between 5 and 10 mg) for mild bronchospasm. It is also available in divided doses.
-
Cerebrovascular Insufficiency
- Cerebrovascular Insufficiency patients should be cautious when taking the drug. Hypotension and bradycardia can further decrease cerebral blood flow.
-
Conductive abnormality
- Consider pre-existing conditions that have reduced heart rate or contractility, such as sick sinus syndrome, before you start the treatment.
-
Diabetes:
- Patients with diabetes should not take beta-blockers as they can mask hypoglycemia symptoms.
-
Heart failure:
- In patients with symptomatic heart disease, beta-blockers should not be used.
- It should not be used in compensated heart failure. Instead, you should use other beta-blockers like bisoprolol or carvedilol.
-
Myasthenia gravis:
- Beta-blockers can be used to increase myasthenia-related muscle weakness, including diplopia or ptosis.
- Patients with myasthenia Gravis should use it with caution.
-
Raynaud and peripheral vascular disease (PVD).
- Patients suffering from Raynaud’s disease or peripheral arterial disease should be cautious when taking the drug.
- It is important to monitor the clinical signs and progression of peripheral arterial disease.
-
Pheochromocytoma:
- Patients with pheochromocytoma need to have adequate alpha-blockade before they can use a beta-blocker.
-
Angina Prinzmetal version:
- Patients suffering from prinzmetal angina should not use Beta-blockers that do not block alpha1-adrenergic receptor activity.
- The presence of unopposed alpha1 receptors can cause coronary vasoconstriction, which can lead to worsening of anginal symptoms.
-
Psoriasis:
- Use of beta-blockers may make psoriasis worse.
-
Renal impairment
- Patients with impaired renal function should be cautious and adjust the dosage.
-
Thyroid disease:
- Hyperthyroidism may be disguised by beta-blockers.
- Avoid abrupt withdrawal from beta-blockers as it can cause a thyroid storm.
Betaxolol (systemic): Drug Interaction
Note: Drug Interaction Categories:
- Risk Factor C: Monitor When Using Combination
- Risk Factor D: Consider Treatment Modification
- Risk Factor X: Avoid Concomitant Use
Risk Factor C (Monitor therapy). |
|
Acetylcholinesterase inhibitors | Beta-Blockers may increase the bradycardic effects. |
Alfuzosin | Might increase the hypotensive effects of Blood Pressure Lowering Agents. |
Alpha1-Blockers | Beta-Blockers can increase the orthostatic hypotensive effects of Alpha1Blockers. Ophthalmic products are less likely to be a risk than systemic ones. |
Aminoquinolines (Antimalarial) | May reduce the metabolism of Beta-Blockers. |
Amiodarone | Beta-Blockers may increase bradycardic effects. Possible to cause cardiac arrest. Amiodarone could increase serum Beta-Blockers. |
Amphetamines | May decrease the antihypertensive effects of Antihypertensive Drugs. |
Antipsychotic Agents (Phenothiazines). | Beta-blockers may intensify the consequences of hypotension. Antipsychotic Agents can slow down the metabolism when taking beta-blockers (Phenothiazines). |
Antipsychotic Agents, Second Generation (Atypical) | Antipsychotic Agents may have an impact on the metabolism of beta-blockers (Phenothiazines). |
Barbiturates | Antipsychotic drugs can have a greater hypotensive effect when blood pressure-lowering medications are used (Second Gen [Atypical]). Beta-Blockers' serum level could be decreased. |
Barbiturates | May intensify blood pressure lowering medications' hypotensive effects. |
Benperidol | May intensify blood pressure lowering medications' hypotensive effects. |
Beta2-Agonists | Beta2-Agonists can have their bronchodilatory effects lessened by beta-blockers (Beta1 selective). Nonselective beta-blockers and greater doses of beta1-selective beta-blockers are of particular concern. |
Bradycardia-Causing Agents | May intensify the bradycardia-causing agents' bradycardic effects. |
Bretylium | Bradycardia Causing Agents may have more bradycardic effects. Atrioventricular (AV) blockage caused by Bretylium may lessen in patients using AV blocking medications. |
Brigatinib | May decrease the antihypertensive effects of Antihypertensive Drugs. Brigatinib could increase the bradycardic effects of Antihypertensive Drugs. |
Brimonidine (Topical) | Might increase the hypotensive effects of Blood Pressure Lowering Agents. |
Bupivacaine | Beta-Blockers can increase serum Bupivacaine concentrations. |
Calcium Channel Blockers (Nondihydropyridine) | BetaBlockers may increase the hypotensive effects. Also, signs of heart disease and Bradycardia have been reported. Calcium Channel Blockers (Nondihydropyridine), may increase serum Beta-Blockers. Exceptions: Bepridil. |
Cardiac Glycosides | Beta-Blockers can increase the bradycardic effects of Cardiac Glycosides. |
Cholinergic Agonists | Beta-Blockers could increase the toxic/adverse effects of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities andbronchoconstriction. Administration: Use these agents with caution and monitor for conduction disorders. Due to the possibility of additive bronchoconstriction, avoid methacholine and any beta-blocker. |
Dexmethylphenidate | Antihypertensive agents may have a less therapeutic effect. |
Diazoxide | May intensify blood pressure lowering medications' hypotensive effects. |
Dipyridamole | The consequences of bradycardia could be amplified by beta-blockers. |
Disopyramide | The consequences of bradycardia could be amplified by beta-blockers. Beta-Blockers may enhance the adverse inotropic impact of disopyramide. |
DULoxetine | By reducing blood pressure, DULoxetine may intensify the hypotensive effects. |
EPINEPHrine (Nasal) | The therapeutic effects of EPINEPHRINE can be diminished by beta-blockers (Beta1 selective). |
EPINEPHrine (Oral Inhalation) | The therapeutic effects of EPINEPHRINE can be diminished by beta-blockers (Beta1 selective). |
Epinephrine (Racemic) | Epinephrine's therapeutic effects can be diminished by beta-blockers (Beta1 selective). |
EPINEPHrine Systemic | Beta-Blockers (Beta1 selective) can reduce the therapeutic effects of EPINEPHrine Systemic. |
Herbs (Hypertensive Properties) | May decrease the antihypertensive effects of Antihypertensive Drugs. |
Herbs (Hypotensive properties) | Might increase the hypotensive effects of Blood Pressure Lowering Agents. |
Hypotension-Associated Agents | Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. |
Insulins | Beta-Blockers can increase the hypoglycemic effects of Insulins. |
Ivabradine | Bradycardia-Causing agents may increase the bradycardic effects of Ivabradine. |
Lacosamide | Bradycardia-Causing Agents can increase the AV-blocking effects of Lacosamide. |
Levodopa-Containing Products | Blood Pressure Lowering Agents can increase the hypotensive effects of Levodopa -Containing Products. |
Lidocaine (Systemic) | Beta-Blockers can increase serum levels of Lidocaine (Systemic). |
Lidocaine (Topical) | Beta-Blockers can increase serum Lidocaine (Topical) concentrations |
Lormetazepam | Might increase the hypotensive effects of Blood Pressure Lowering Agents. |
Mepivacaine | Beta-Blockers can increase serum levels of Mepivacaine. |
Methoxyflurane | May increase the hypotensive effects of Beta-Blockers. |
Methylphenidate | May decrease the antihypertensive effects of Antihypertensive Drugs. |
Midodrine | May increase the bradycardic effects of Bradycardia Causing Agents. |
Molsidomine | Might increase the hypotensive effects of Blood Pressure Lowering Agents. |
Naftopidil | Might increase the hypotensive effects of Blood Pressure Lowering Agents. |
Nicergoline | Might increase the hypotensive effects of Blood Pressure Lowering Agents. |
Nicorandil | Might increase the hypotensive effects of Blood Pressure Lowering Agents. |
NIFEdipine | May increase the hypotensive effects of Beta-Blockers. NIFEdipine could increase the negative inotropic effects of Beta-Blockers. |
Nitroprusside | The hypotensive effects of Nitroprusside may be enhanced by blood pressure lowering agents. |
Nonsteroidal Anti-Inflammatory Drugs | BetaBlockers may have a lower antihypertensive impact. |
Opioids (Anilidopiperidine) | The consequences of bradycardia could be amplified by beta-blockers. Other opioids, such as anilidopiperidine, may enhance the hypotensive effects of beta-blockers. |
Pentoxifylline | May intensify blood pressure lowering medications' hypotensive effects. |
Pholcodine | By reducing blood pressure, pholocdine may exacerbate hypotension. |
Phosphodiesterase 5 Inhibitors | May intensify blood pressure lowering medications' hypotensive effects. |
Propafenone | Possibly raising serum beta-blockers. Even by itself, propafenone has some beta-blocking properties. |
Prostacyclin Analogues | May intensify blood pressure lowering medications' hypotensive effects. |
Quinagolide | May intensify blood pressure lowering medications' hypotensive effects. |
Regorafenib | The consequences of bradycardia could be amplified by beta-blockers. |
Reserpine | May intensify beta-blockers' hypotensive effects. |
Rifamycin Derivatives | In serum, beta-blockers might be decreased. Exceptions: Rifabutin. |
Ruxolitinib | May increase the bradycardic effects of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labels recommend that bradycardia-causing agent be avoided to the greatest extent possible. |
Sulfonylureas | Sulfonylureas' hypoglycemic effects can be enhanced by beta-blockers. Beta blockers that are not cardioselective may be more harmful than those that are. All beta-blockers appear to be able to conceal tachycardia as the early indication of hypoglycemia. In comparison to systemic medications, ophthalmic beta blockers are probably associated with a decreased risk. |
Terlipressin | Bradycardia Causing Agents may have more bradycardic effects. |
Theophylline Derivatives | Theophylline Derivates can have their bronchodilatory effects lessened by beta-blockers (Beta1 selective). Monitoring: Keep an eye out for any diminished theophylline effectiveness when taking a beta-blocker at the same time. Beta-1 selective drugs may lose their selectivity at larger doses, although they are less likely to antagonise beta-phylline than nonselective drugs. |
Tofacitinib | May increase the bradycardic effects of Bradycardia Causing Agents. |
Yohimbine | May decrease the antihypertensive effects of Antihypertensive Drugs. |
Risk Factor D (Consider therapy modifications) |
|
Alpha2-Agonists | Beta-Blockers may have an AV-blocking effect that is greater. It is possible to increase the risk of sinus node dysfunction. Beta-Blockers can increase the rebound hypertensive effect Alpha2Agonists. This can happen if the Alpha2-Agonist abruptly withdraws. Treatment: Monitor your heart rate closely while you are taking clonidine and beta blockers. When possible, stop taking beta blockers a few days before you begin clonidine withdrawal. Also, monitor your blood pressure carefully. Other alpha2-agonists will not be recommended. Exceptions: Apraclonidine. |
Amifostine | Amifostine's hypotensive effects may be enhanced by blood pressure lowering agents. Treatment: Blood pressure lowering drugs should be stopped 24 hours before amifostine administration. Amifostine should be avoided if blood pressure lowering medication cannot be withheld. |
Ceritinib | Bradycardia-inducing substances may intensify the bradycardic effects of ceritinib. Management: If the combination is not possible, keep a close eye out for bradycardia symptoms in patients, and closely monitor blood pressure and heart rate throughout treatment. Various monographs will go through the exceptions. |
Dronedarone | Beta-blockers may intensify the consequences of bradycardia. Dronedarone may elevate serum levels of beta-blockers. This is most likely accurate only for substances that use CYP2D6 for metabolism. Treatment: It is advised to start taking beta-blockers at lower doses. The patient's ability to tolerate the combination should be confirmed by the results of the ECG. |
Ergot Derivatives | The vasoconstrictive effects of ergot derivatives can be enhanced by beta-blockers. The exception is Nicergoline. |
Fingolimod | Fingolimod may intensify beta-blockers' bradycardic effects. Avoid using fingolimod and beta-blockers concurrently, if at all feasible. Overnight ECG abnormalities in patients who need coadministration should be watched for. Bradycardia should be kept an eye on in patients. |
Grass Pollen Allergen Extract (5 Grass Extract) | Beta-Blockers could increase the toxic/adverse effect of Grass Pollen Extract (5 Grass) Beta-Blockers can also inhibit the effectiveness of epinephrine to treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract). Other effects of epinephrine might not be affected or even increased by Beta-Blockers. |
Obinutuzumab | This may increase the hypotensive effects of Blood Pressure Lowering Agents. Management: You may temporarily withhold blood pressure lowering medication beginning 12 hours before obinutuzumab injection and continuing for 1 hour after infusion. |
Siponimod | Bradycardia-Causing Drugs can increase Siponimod's bradycardic effects. Management: Siponimod should not be taken with bradycardia-causing drugs. |
Risk Factor X (Avoid Combination) |
|
Bromperidol | Bromperidol's hypotensive effects may be enhanced by Blood Pressure Lowering agents. Bromperidol could decrease the hypotensive effects of Blood Pressure Lowering agents. |
Floctafenine | Beta-Blockers may have an adverse/toxic effect that can be increased. |
Methacholine | Beta-Blockers can increase the toxic/adverse effects of Methacholine. |
Rivastigmine | Beta-Blockers may increase the bradycardic effects. |
Monitoring parameters while using Betaxolol:
- Montor Blood pressure, pulse, and renal functions
Target Blood pressure:
- Target blood pressure of less than 130/80 mmHg in patients with hypertension and known cardiovascular disease or the 10-year ASCVD risk is greater than 10%.
- The target blood pressure of less than 130/80 mmHg may be reasonable in patients with ASCVD risk.
- Target blood pressure of less than 140/90 mmHg in patients aged 18 – 65 years with Diabetes and hypertension without cardiovascular disease and the 10-year ASCVD risk is less than 15%.
- Target blood pressure of less than 130/80 mmHg in patients aged 18 – 65 years with Diabetes, hypertension, cardiovascular disease, or the 10-year ASCVD risk is greater than 15%.
- Target blood pressure of less than 140/90 mmHg in patients aged more than 65 years and without major comorbid conditions.
- Target blood pressure of less than 150/90 mmHg in patients aged more than 65 years and poor health or comorbid conditions.
How to take Betaxolol?
It may be taken with or without meals as its absorption is not affected by food.
Mechanism of action of Betaxolol:
- It blocks beta-1 receptors in a competitive manner, but has minimal or no effect on beta-2.
- It takes approximately 1 to 1.5 hours for it to take effect.
- The drug can be taken orally and almost all of it (100%) is eliminated.
It is 50% protein-bound and metabolized by your liver to multiple metabolites.
It has a bioavailability rate of 89% and a half life elimination time of 14 to 22 hours.
Patients with renal and liver disease have a longer half-life.
It takes approximately 1.5 to 6 hours to reach peak serum concentration.
The drug excreted in this form is more than 80%.
Betaxolol Brand Names (International):
- Beof
- Bertocil
- Betac
- Betakor
- Betarun
- Betasel S
- Betaxen
- Betaxol
- Betoptima
- Betoquin
- Bexolo
- Daberol
- Kerlon
- Kerlone
- Lokren
- Optibet
- Optipres
- Presmin
- Vistagan
Betaxolol Brand Names in Pakistan:
Betaxolol Eye Drops 0.5 %w/v |
|
Betaxen | Innvotek Pharmaceuticals |
Betaxol | Atco Laboratories Limited |
Betaxolol Eye Drops 0.25 %w/v |
|
Betoptic | Novartis Pharma (Pak) Ltd |
Betoptic S | Novartis Pharma (Pak) Ltd |